Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$983000.0.

  • Atara Biotherapeutics' Change in Account Payables rose 6839.23% to -$983000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 5802.67%. This contributed to the annual value of $687000.0 for FY2024, which is 12194.89% up from last year.
  • Per Atara Biotherapeutics' latest filing, its Change in Account Payables stood at -$983000.0 for Q3 2025, which was up 6839.23% from -$83000.0 recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Change in Account Payables peaked at $2.5 million during Q3 2023, and registered a low of -$4.6 million during Q1 2022.
  • Its 4-year average for Change in Account Payables is -$1.0 million, with a median of -$983000.0 in 2025.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 36834.45% in 2024, then crashed by 26113.8% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Change in Account Payables (Quarter) stood at -$4.5 million in 2022, then surged by 36.85% to -$2.8 million in 2023, then surged by 179.12% to $2.2 million in 2024, then tumbled by 144.2% to -$983000.0 in 2025.
  • Its last three reported values are -$983000.0 in Q3 2025, -$83000.0 for Q2 2025, and -$3.0 million during Q1 2025.